secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hepion Pharmaceuticals, Inc. (HEPA)
CIK:        0001583771
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001493152-24-047182
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Hepion Pharma receives Nasdaq delisting notice due to stockholder deficit and failure to meet listing alternatives
--------------------------------------------------------------------------------

- Stockholders' deficit of ($406,685) as of Sept 30, 2024 triggers Nasdaq Listing Rule non-compliance.
- Company fails to meet alternatives: $35M market value or $500K net income in recent fiscal years.
- Nasdaq gives 45 days to submit a compliance plan; extension of up to 180 days possible.
- Common stock (HEPA) continues trading on Nasdaq Capital Market while cure process is pending.
- No assurance that listing will be maintained; potential for hearing panel appeal if plan rejected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583771/000149315224047182/0001493152-24-047182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583771/000149315224047182/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-047182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer